223677-02-9

Upstream product

• 94-30-4 ethyl 4-methoxybenzoate 
• 3618-04-0 trans-4-hydroxy-cyclohexane carboxylic acid ethyl ester 
• 74-88-4 methyl iodide 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 99-96-7 4-hydroxy-benzoic acid 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 3685-26-5 trans-4-hydroxycyclohexanecarboxylic acid 

Downstream Products

• 223677-08-5 1-Hydroxymethyl-4-methoxy-cyclohexanecarboxylic acid ((S)-1-methylcarbamoyl-2-phenyl-ethyl)-amide 
• 1082739-44-3 C₁₆H₂₁FO₃ 
• 120552-57-0 4-methoxycyclohexane-1-carbaldehyde 
• 101869-74-3 (4-methoxy-cyclohexyl)-methanol 

Relevant academic research and scientific papers

SSAO INHIBITORS AND USE THEREOF

Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

Design and synthesis of thiol containing inhibitors of matrix metalloproteinases

A series of thiol containing derivatives was prepared. Several of these compounds were found to inhibit matrix metalloproteinases 1, 3, and 9 with selectivity towards 3 and 9. Compounds 15, 20 and 22 were administered to rats orally at 75 μmol/kg. Drug levels of compounds 20 and 22 in the plasma were found to exceed the IC50 values for MMP 3 and 9 four hours after administration.